A Prospective Safety Sub-Registry to Assess Anaphylaxis and Severe Allergic Reactions, and Severe Cutaneous and Systemic Immune-Mediated Reactions with Alglucosidase Alfa Treatment (Pompe Safety Sub-Registry)

02/04/2015
14/03/2024
EU PAS number:
EUPAS9194
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

rdct- lts13930-aglu06909-amended-protocol2-PDFA

English (466.25 KB - PDF) View document
Study results
Study results

rdct- lts13930-CSR Abstract-PDFA

English (629.01 KB - PDF) View document
Study report
Other information